Business Overview
Rafael Holdings is a biotechnology company developing pharmaceuticals and holding interests in clinical and early-stage companies. The company's primary focus is completing development of Trappsol Cyclo through its ongoing Phase 3 clinical trial for Niemann-Pick Disease Type C1 and bringing it to regulatory approval, while maintaining a diversified portfolio including LipoMedix, Cornerstone Pharmaceuticals, Rafael Medical Devices (which received FDA clearance for the VECTR System in December 2024), and Day Three Labs. In March 2025, the company consummated a merger with Cyclo, making it a wholly-owned subsidiary.
Segment Performance
Product revenue declined from $243 thousand (nine months ended April 30, 2025) to $368 thousand (nine months ended April 30, 2026), though Q3 2026 revenue was only $179 thousand compared to $362 thousand in Q3 2025. Infusion Technology revenue was $42 thousand in Q3 2025 with no revenue in Q3 2026. Rental revenue from third parties was $173 thousand (nine months 2026) versus $147 thousand (nine months 2025). Total nine-month revenue increased modestly to $630 thousand from $567 thousand year-over-year, but operating losses increased significantly to $23.7 million from $16.4 million.
Key Risk Factors
The company faces significant risks including substantial operating losses (consolidated net loss of $19.0 million for the nine months ended April 30, 2026), with continued cash burn that may impact liquidity despite current cash of $30.5 million. Clinical development and regulatory approval risks exist for Trappsol Cyclo and other pipeline candidates. The company has significant concentration in revenue from a limited number of customers and related parties (one third-party customer representing 30% of nine-month revenue). Additionally, the company is evaluating its portfolio holdings to determine optimal focus on core assets, creating uncertainty around strategic direction and potential impairments.
